The patient received empiric antibiotic therapy (day 24–26 pd) and COVID-19-specific treatment with remdesivir (days 26–37 pd), dexamethasone (days 26–53 pd), Tocilizumab (a mAb against interleukin-6 receptor, day 31 pd) and high-flow oxygen supplementation until day 45 pd when they developed rapidly progressing acute hypoxemic respiratory failure. Here, IL6R is linked to respiratory failure.